SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is under pressure after reports that Microsoft is winding down its deal to rent Oracle AI cloud capacity, amid broader worries about debt-funded data-center expansion and possible permitting or regulatory delays. Traders disagree on the impact: some view the arrangement as a limited or older contract whose capacity can be re-leased, while others see it as a warning about AI demand, backlog quality, and Oracles leverage.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts reported wind-down of an Oracle AI-compute rental deal is driving discussion, with traders debating whether it signals weaker AI infrastructure spending or a shift away from older capacity toward newer GPUs and other providers. The uncertainty is feeding broader concerns about data-center delays and hyperscaler capex, while some traders argue the change is a limited hardware or partner reshuffle rather than a retreat from AI investment.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is under pressure amid a wider AI and semiconductor selloff, with traders linking the weakness to fears that political shifts could slow data-center construction and hyperscaler AI spending. The community is split between concerns about customer concentration and capex financing and the view that AI demand and Broadcoms fundamentals remain intact.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings sharp selloff follows a Q3 earnings and revenue miss and a steep cut to its FY26 EBITDA outlook, which the company attributed largely to increased investment in its Predictions business. Traders are split on whether that spending can build a profitable growth engine, with skeptics citing cash burn, competition from Kalshi and Polymarket, and weak management execution.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

A sharp semiconductor-sector selloff has focused attention on fears that election-driven resistance to data-center construction could slow AI infrastructure spending and chip demand. Traders are split between viewing the decline as an overreaction, with projects likely to shift locations, and worrying that AI demand and memory valuations may weaken; volatile rebound attempts have added to the debate.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Fireflys engine, technology-licensing and engineering-support agreement with AST SpaceMobile for its planned heavy-lift rocket is driving attention, with traders viewing it as a major validation of Fireflys propulsion business and a boost to its funding and production plans. The sharp rally has prompted bullish reactions, alongside caution about the deals cash-and-stock terms, execution risks and whether the gains will hold.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axons quarterly results missed expectations and its lower full-year outlook, citing federal procurement delays, sparked a sharp selloff and fresh lows. Traders are divided between buying the dip on the companys growth prospects and warning that its high valuation leaves little room for weaker results.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is drawing attention ahead of the FDAs pending decision on deramiocel for Duchenne muscular dystrophy, a binary catalyst for the company. Many traders expect approval, citing HOPE-3 upper-limb data and support from 28 physician-scientists, while others warn that the FDA could still issue a rejection; short-squeeze expectations are adding to the bullish positioning.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs stronger-than-expected quarterly results and higher full-year revenue outlook are driving the rally, with traders also pointing to a larger backlog and commercial momentum. Bullish reactions are tempered by concerns about cash burn, dilution, and how much reported growth reflects acquisitions rather than the core quantum business.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs quarterly report and earnings call are driving a sharp-rebound discussion: traders point to rapid AI-cloud growth, a larger contracted backlog and customer-funded GPU spending as support for its shift from bitcoin mining to AI infrastructure. Skeptics counter that a pushed-out ARR timeline, substantial financing needs and a Microsoft-related deployment delay leave uncertainty over whether the rally can last.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that updated data from a Phase 1b/2 trial of zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), will be shared tomorrow at the North American...

Zai Lab Limited (ZLAB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Zai Lab Limited (ZLAB) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma, today announced financial results for the third quarter of 2026, along with recent product highlights and corporate updates. We are approaching a defining period for Zai Lab, as we advance toward bringing our first...

Zai Labs Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today shared the first data from a global Phase 1b clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) in combination with atezolizumab with and without carboplatin as first-line...

Zai Lab Announces $250 Million Private Placement

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) an innovation-driven, global biopharma company, today announced that it has entered into a securities purchase agreement for the sale of 11,340,000 American Depositary Shares (ADSs), each representing ten ordinary shares of the Company, to certain...

Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its third quarter 2026 financial results and provide recent corporate updates on November 5, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00...

Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31R Bispecific Antibody, for Atopic Diseases

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from the first clinical trial evaluating ZL-1503, the companys internally developed interleukin-13 (IL-13) and interleukin-31 (IL-31)R bispecific antibody, will be shared for the first time at the American College of Allergy...

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that global data from a clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) will be shared for the first time at the European Society for...

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. Study met its primary endpoint...

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

$ZLAB Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.40 down -33.33% YoY
• Reported revenue of $108.21M down -6.79% YoY
• Zai Lab expects its commercially profitable China business to return to growth in 2027 and is positioned for a return to meaningful growth as patient access expands for key products.

Stocktwits

Zai Lab Ltd

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.40 down -33.33% YoY
• Reported revenue of $108.21M down -6.79% YoY
• Zai Lab expects its commercially profitable China business to return to growth in 2027 and is positioned for a return to meaningful growth as patient access expands for key products.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of -$0.40 down -33.33% YoY
• Reported revenue of $108.21M down -6.79% YoY
• Zai Lab expects its commercially profitable China business to return to growth in 2027 and is positioned for a return to meaningful growth as patient access expands for key products.

Zai Lab reported lower year-over-year revenue and a larger net loss, including inventory write-downs, while its partner discontinued the Sjgrens disease Phase 3 study for futility.

Zai Lab reported zocis 81.8% confirmed ORR and 81.9% estimated six-month PFS, advanced its global Phase 3 plan, and cited positive Phase 3 myositis results and ZL-1503 milestones.

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Zai Lab Limited - ADR

Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug

Equity

Neutral Sentiment

Zai Lab (ZLAB) announced on Wednesday that it plans to await the results of a trial evaluating Bemarituzumab in combination with Nivolumab and chemotherapy before filing for regulatory approval for the experimental cancer drug.The data from the trial is expected by the end of 2025 or the first half of 2026, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0903/2025090302254.pdf">said</a> in a filing with the Hong Kong stock exchange. Nasdaq-listed <a href="https://stocktwits.com/symbol/ZLAB">shares of Zai Lab</a> were down 4% at the time of writing.On Stocktwits, retail sentiment around ZLAB stayed within ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.The announcement from the company follows its partner Amgen's (AMGN) completion of the final analysis of the late-stage trial evaluating Bemarituzumab in combination with Chemotherapy in first-line gastric cancer.Amgen <a href="https://stocktwits.com/news-articles/markets/equity/amgen-cancer-drug-improves-survival-in-late-stage-trial/chmZZAcRR79">said</a> in late June that Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival as compared to placebo plus chemotherapy in people living with certain types of unresectable locally advanced or metastatic gastric or gastroesophageal junction cancer. Overall survival refers to the total length of time a patient with cancer remains alive after diagnosis or the initiation of treatment.However, Zai Lab said on Wednesday that, upon final analysis of the trial, the magnitude of the previously observed survival benefit was reduced, leading the company to await the results of another trial.Zai Lab holds co-development and commercialization rights for Bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan.ZLAB shares are up 22% this year and approximately 66% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-reports-near-four-percent-jump-in-us-vehicle-sales-in-august/chwT6RHRd8r">Ford Reports Near 4% Jump In US Vehicle Sales In August</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Zai Lab company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

The company holds co-development and commercialization rights for Bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan.

AMGEN Inc.

Fundamental investor

Technical trader

A mix of both

Fundamental analysis looks at earnings, valuation, and business quality, while technical analysis focuses on chart patterns, price action, and indicators, and many investors blend the two. How do you decide what to buy: fundamentals or technicals? Vote and explain your reasoning in the comments.

Current Price	$25.85
Prev Close	$22.60
Open	$23.40
Dividend Yield	0.00%
50-Day Moving Average	$24.64
Beta	1.06
Avg. Volume	1.02M
PE Ratio	-13.28

52-Week High	$27.50
52-Week Low	$15.96
Market Capitalization	$2.55B
EPS (Annual)	-$1.61
Price to Book	4.18
Revenue Per Employee	$258,617.15

Feed

News

Sentiment

Earnings

Fundamentals

Info

ZLAB Fundamentals